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were most pronounced in the lateral compartment. Mean reduction
in JSW was lower with rhFGF18 than with placebo in the lateral
compartment, where an increase in JSW was observed in the high-
dose group (10mg: −0.02±0.86, 30mg: 0.00±0.73, 100mg: 0.34±0.90,
placebo: −0.18±0.74, overall p-value = 0.0077). Strong improvements in
WOMAC scores vs. baseline were observed in all groups: function scores
10mg: −15.76±13.72, 30mg: −12.12±12.06, 100mg: −11.28±15.30, placebo:
−17.02±13.56, overall p-value=0.0322; pain scores 10mg: −4.10±5.11,
30mg: −3.54±3.67, 100mg: −2.87±4.76, placebo: −5.56±4.17, overall
p-value=0.0044. However, no improvement of active vs. placebo was
demonstrated. No local or systemic safety signals were observed.
Acute inﬂammatory reactions were slightly more common with active
treatment, but this was not dose-dependent; no increase in knee pain
and no safety issues emerged. Serum FGF18 levels (SAD cohorts) were
below the lower limit of quantiﬁcation at all time points in all subjects.
Conclusions: In this PoC study, i.a. injection of rhFGF18 was associated
with a signiﬁcant dose-dependent improvement in total femorotibial
cartilage volume and JSW. No local or systemic safety issues emerged
and treatment was well tolerated. All patients on rhFGF18 experienced
symptom improvement vs. baseline, with a placebo response higher than
active treatment. rhFGF18 is a promising DMOAD that warrants further
long-term clinical investigation.
66
ROLE OF VITAMIN D IN OSTEOARTHRITIS KNEE: A SIX MONTH
DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROL TRIAL
D. Sanghi1, R.N. Srivastava1, S. Agarwal2, S.M. Natu1, A. Singh1,
S. Avasthi3. 1CSM Med. Univ., Lucknow, India; 2SGPGIMS, Lucknow, India;
3GSVM Med. Coll., kanpur, India
Purpose: There is a putative role of vitamin D in osteoarthritis (OA)
based on animal, epidemiological and human clinical studies. Short term
clinical studies suggest beneﬁcial inﬂuence of vitamin D on local changes
in the bone which probably accounts for diminished pain experienced in
knee OA (KOA). Inadequate sunlight exposure and lower serum levels of
25(OH)D appears to be associated with an increased risk for progression
of OA knee. Some chronic analgesic users with OA knee were more
likely to be in lower categories of 25(OH) D compared to women with
asymptomatic OA. On the basis of above background this study was
planned to assess the effect of vitamin D on the progression of disease
Methods: A six month, double blind, randomized and placebo controlled
trial of vitamin D, in vitamin D insufﬁcient OA knee subjects (serum
25 (OH) D levels <50nmol/L) was conducted. 150 subjects of primary
OA knee, diagnosed by ACR guidelines, were subjected to personal
interview to determine their vitamin D intake (by 3 day dietary recall and
food frequency table) and the daily sunlight exposure in hours. Serum
levels of calcium, phosphorus, alkaline phosphatase and 25(OH) D were
measured to determine their vitamin D proﬁle. We identiﬁed 64 vitamin
D insufﬁcient subjects out of 150 primary OA knee patients. These were
randomized by random allocation table for intervention. In cases a bolus
dose of calciferol in 60,000 IU/day for 10 days followed by 60,000
IU/month for six months was administered and in controls a placebo in
the same schedules and durations was given. Primary outcome measures
were clinical WOMAC scores (pain, stiffness and physical function) and
VAS for knee pain. Secondary outcome measures were radiological
features (joint space width, osteophyte scores, subchondral sclerosis
scores and tibio femoral alignment) and KL grades. The serum levels
of vitamin D were assessed by using Enzyme Linked Immunosorbent
Assay (ELISA) and calcium /phosphorus/alkaline phosphatase by UV end
point method. Statistical analysis was performed on an intension to treat
basis.
Results: There was no signiﬁcant baseline difference of age, sex, analgesic
frequency, dietary vitamin D intake, serum levels of vitamin D, calcium,
phosphorus, alkaline phosphatase and in clinical and radiological scores
between the cases and controls. BMI (25.96 vs 25.65, p = 0.75) and pain
(10.94 vs 10.64, p = 0.66) was higher in the placebo group although
difference was not statistically signiﬁcant. There was no signiﬁcant
difference in radiological features and KL grades from baseline and at
6 months in both the groups.At six months, both the groups had an
improvement in WOMAC and VAS pain scores but vitamin D showed
beneﬁt over placebo from baseline (p < 0.01); for WOMAC physical
function vitamin D group showed signiﬁcant improvement over placebo
which remained same as their base line levels.
Conclusions: Although a long term study is being recommended to
establish radiological progression, if any, this short term randomize
placebo control trial yields a beneﬁcial effect of vitamin D in pain and
physical function outcomes in KOA.Vitamin D intake was beneﬁcial in
symptomatic improvement of KOA.
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Purpose: Knee joint distraction (KJD) is a new treatment for end-stage
osteoarthritis (OA) of the knee that temporarily unloads the femorotibial
cartilage and subchondral bone. This technique was previously shown to
be clinically effective at 1 year follow-up. Clinical improvement coincided
with the signiﬁcant increase of joint space width and cartilage thickness,
decrease in denuded bone areas, and decrease of bone sclerosis. The
current study provides 2 year follow-up results on the effect of KJD.
Methods: The open, uncontrolled study included 20 patients (age
49±6 years; 11 females) with end-stage knee OA, considered for total
knee replacement. Patients were treated with KJD for 2 months. The
study was approved by the medical ethical committee (METC) of the
University of Utrecht and all patients gave written informed consent.
Two monotubes with internal coil springs were placed parallel on the
medial and lateral side, bridging the knee joint, creating a distance
between both cartilage surfaces of 5mm, conﬁrmed by X-ray. Patients
were encouraged to load the knee during distraction, in order to attain
intermittent intra-articular ﬂuid pressures. After 2 months, tubes and
pins were removed.
The primary clinical outcome parameter was pain and function by
use of the ‘Western Ontario McMasters University Index’ (WOMAC)
questionnaire, with a visual analoge pain score (VAS) as secondary
outcome. The primary structural outcome was minimal joint space width
(JSW) on semi-ﬂexed, anterior-posterior, weight bearing radiographs
(Buckland-Wright, MTP) analyzed by digital interactive computer
analysis (KIDA). Secondary structural outcomes were quantitative MRI
parameters of cartilage morphology, analyzed by Chondrometrics Gmbh
(Ainring, Germany). Additionally, biomarkers for synthesis (sPIIANP) and
breakdown (uCTXII) of collagen type II were evaluated.
Results: Total WOMAC score increased from 45%±3.6 at baseline to
78%±4.8 at 2 years (p < 0.000) and the VAS pain score decreased from
73±2.1 at baseline to 28±6.0mm at 2 years (p< 0.000). The clinical
improvement coincided with structural tissue changes: the minimum
JSW increased from 1.0±0.3 to 1.8±0.3mm (p < 0.03) at 2 years;
quantitative MRI analysis corroborated this result by an increase in
cartilage thickness over total subchondral bone area (ThCtAB) of the
most affected compartment (from 2.4±0.1 at baseline to 2.8±0.1mm at
2 years; p < 0.05) and a decrease of the percentage of subchondral bone
area that was denuded (dABp: change from 22±5 at baseline to 8±2% at
2 years; p < 0.004). MRI and X-ray changes were moderately correlated
(r = 0.67 p < 0.000).
Biomarker analysis shows that, directly after treatment from 6 months
follow-up to 2 years, the average change in the ratio of PIIANP / CTXII
changed in favor of collagen type II synthesis (p < 0.003).
Conclusions: Joint distraction results in signiﬁcant improvement in the
clinical (pain) and structural (cartilage) status in end-stage knee OA
which is sustained for at least 2 years. We have shown previously
that this clinical improvement is seen already one month after KJD
treatment.
MRIs suggest an increase in cartilage thickness and covering of denuded
areas in comparison with baseline values. The mechanical competence of
the formed tissue is suggested by increased JSW of weight-bearing X-ray,
and the hyaline nature by collagen type II biomarker analysis. Structural
changes over 1 year were slightly greater compared with those over
2 years follow-up suggesting that the main therapeutic effect occurs in
the ﬁrst year, and is maintained in the 2nd year. At present, distraction
therapy appears to be the ﬁrst treatment that can reverse cartilage
damage in end-stage knee osteoarthritis accompanied by signiﬁcant
clinical improvement.
